GlassScriptPhysician profile
Antonio Sandoval
NPI 1053934729
$4,512.95
in general payments reported to CMS, 2019-2025
22 companies · $643 in 2025
The $643 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $357 · 2022: $1,087 · 2023: $1,345 · 2024: $1,082 · 2025: $643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,050 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,049.53 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $865.78 | 2021-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $702.06 | 2022-2024 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $686.05 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $645.55 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $296.47 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $250.94 | 2022-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $200.81 | 2021-2024 | Jardiance, Synjardy |
| Neurocrine Biosciences, INC. | $140.20 | 2024 | Ingrezza |
| Abbvie INC. | $138.74 | 2021-2024 | |
| Exact Sciences Corporation | $137.16 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $88.38 | 2023-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Pfizer INC. | $59.02 | 2023-2024 | |
| Si-Bone, INC. | $48.33 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $47.83 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.50 | 2025 | Xifaxan |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $42.24 | 2023 | Quviviq |
| Medtronic, INC. | $40.50 | 2024 | Minimed 780g, Intellis Adaptivestim |
| Viiv Healthcare Company | $20.13 | 2024 | Apretude |
| Inspire Medical Systems, INC. | $16.23 | 2023 | Inspire |
| Gilead Sciences, INC. | $15.60 | 2024 | |
| Phathom Pharmaceuticals, INC. | $15.48 | 2024 | Voquezna |
| Amarin Pharma, INC. | $11.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonio Sandoval listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.